Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study
- 430 Downloads
Dronabinol (Δ9tetrahydrocannabinol) is approved for HIV-related anorexia, yet, little is known about its effects in HIV-positive marijuana smokers. HIV-negative marijuana smokers require higher than recommended dronabinol doses to experience expected effects.
Employing a within-subjects, double-blind, placebo-controlled design, we assessed the effects of repeated high-dose dronabinol in HIV-positive marijuana smokers taking antiretroviral medication.
Participants (N = 7), who smoked marijuana 4.2 ± 2.3 days/week, resided in a residential laboratory for two 16-day stays, receiving dronabinol (10 mg QID) in one stay and placebo in the other. Efficacy was assessed with objectively verified food intake and body weight. Tolerability was measured with sleep, subjective, and cognitive assessments. For analyses, each inpatient stay was divided into two phases, days 1–8 and 9–16; we compared dronabinol’s effects with placebo in each 8-day phase to investigate tolerance.
Despite sustained increases in self-reported food cravings, dronabinol only increased caloric intake in the initial 8 days of dosing. Similarly, sleep quality was improved only in the first 8 days of dosing. Dronabinol’s mood-enhancing effects were sustained across the 16-day inpatient stay. Dronabinol was well tolerated, causing few negative subjective or cognitive effects.
In HIV-positive marijuana smokers, high dronabinol doses safely and effectively increased caloric intake. However, repeated high-dose dronabinol appeared to result in selective tolerance to these effects. These findings indicate that HIV-positive individuals who smoke marijuana may require higher dronabinol doses than are recommended by the FDA. Future research to establish optimal dosing regimens, and reduce the development of tolerance, is required.
KeywordsHIV Dronabinol THC Appetite stimulation Anorexia
Thanks to Brooke Roe, Diana Paksarian, and Michael Rubin for assistance in data collection, and to Jennifer Redman for input into interpretation of sleep measurements. This study complies with the laws of the country in which it was performed (USA).
National Center for Complementary and Alternative Medicine (DA0126980).
The authors have no conflicts to declare.
- Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M (2003) Short-term effects of cannabinoids in patients with HIV-1 infection. Ann Intern Med 139:258–266PubMedGoogle Scholar
- American Psychiatric Association (1994) DSM-IV: diagnostic and statistical manual of mental disorders. American Psychiatric AssociationGoogle Scholar
- Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW, Shepard KV (1997) Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 14:7–14CrossRefPubMedGoogle Scholar
- Grinspoon L, Bakalar JB (1997) Marihuana: the forbidden medicine. Yale University Press, New HavenGoogle Scholar
- Institute of Medicine (1999) Marijuana and medicine: assessing the science base. Institute of Medicine, Washington DCGoogle Scholar
- Johnson M, Charlebois E, Morin SF, Catz SL, Goldstein RB, Remien RH, Rotheram-Borus MJ, Mickalian JD, Kittel L, Samimy-Muzaffar F, Lightfoot MA, Gore-Felton C, Chesney A, Team NHLP (2005) Perceived adverse effects of antiretroviral therapy. J Pain Symptom Manage 29:193–205CrossRefPubMedGoogle Scholar
- Sheskin DJ (2000) Handbook of parametric and nonparametric statistical procedures, 2nd edn. CRC Press LLC, Boca RatonGoogle Scholar